Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network I. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkins lymphomas. 2016. Available from: http://www.nccn.org.
   Google Scholar
• National Cancer Institute. SEER Stat Fact Sheets: Non-Hodkins Lymphoma. Available from: http://seer.cancer.gov/statfacts/html/clyl.html.
   Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33:2516–2522.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1087–1097.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–3071.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27:1607–1614.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579–4586.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853–2858.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–1344.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Gazyva Package Insert 2017 [cited 2017]. Available from: www.gene.com/download/pdf/gazyva_prescribing.pdf
   Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health. 2003;6:9–17.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford University Press; 2016.
   Google Scholar
• Hiddemann W, Barbui AM, Canales Albendea MA, et al. Immunochemotherapy with obinutuzumab or rituximab in previously untreated follicular lymphoma in the randomized Phase III GALLIUM study: analysis by chemotherapy regimen. Hematol Oncol. 2017;35:117–119.
   Google Scholar
• Genentech, Inc. GALLIUM Clinical Study Report. 2017. Data on file.
   Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P, et al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Am Soc Hematology. 2017.
   Google Scholar
• Seymour JF, Feugier P, Offner F, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Am Soc Hematology. 2013.
   Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13:e0196007.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol. 2008;19:570–576.
   PubMed Web of Science ®Google Scholar
• Wild D, Walker M, Pettengell R, et al. PCN62 Utility Elicitation in patients with follicular lymphoma. Value Health. 2006;9:A294.
   Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Medicare Fee-for-Service Part B Drugs 2017 [2017 Nov 1]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.html
   Google Scholar
• Centers for Medicare and Medicaid Services. Physician Fee Schedule Search. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/index.html?redirect=/PhysicianFeeSched/.
   Google Scholar
• Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National Lympho Care Study. Br J Haematol. 2018.
   Web of Science ®Google Scholar
• Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096–1101.
   PubMed Web of Science ®Google Scholar
• Castro Gomez AJ, Lopez-Guillermo A, Rueda Dominguez A, et al. Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line. Revista espanola de salud publica. 2012;86:163–176.
   PubMed Web of Science ®Google Scholar
• Chen Q, Ayer T, Nastoupil LJ, et al. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health. 2015;18:189–197.
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Bagust A, Boland A, et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: a NICE single technology appraisal. PharmacoEconomics. 2013;31:403–413.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Chien R, Friedmann M, et al. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma. 2012;53:2371–2377.
   PubMed Web of Science ®Google Scholar
• Pereira C, Rubio TC, Rubio RD. Cost-effectiveness analysis of maintenance treatment with rituximab in patients with follicular lymphoma responding to first line induction therapy in portugal. Value Health. 2014;17:A530–A531.
   PubMed Web of Science ®Google Scholar
• Soini EJ, Martikainen JA, Vihervaara V, et al. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma. Clin Ther. 2012;34:915–925.e2.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Longo DL. Which anti-CD20 antibody is better in follicular lymphoma?. N Engl J Med. 2017;377:1389–1390.
   PubMed Web of Science ®Google Scholar
• Nair R, Tabchi S, Hagermeister F. Obinutuzumab treatment of follicular lymphoma. N Engl J Med. 2017;377:2605–2606.
   PubMed Web of Science ®Google Scholar